Merck kills Tredaptive worldwide
This article was originally published in Scrip
Executive Summary
Merck & Co is withdrawing its troubled dyslipidemia drug Tredaptive (niacin plus laropiprant) in all markets where it is available. The decision comes the same day that the European Medicines Agency's Pharmacovigilance Risk Assessment Committee decided that the product's risks outweighed its benefits and recommended its suspension.